更新于：2024-05-06
Neostigmine Methylsulfate
甲硫酸新斯的明
更新于：2024-05-06
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C13H22N2O6S |
InChIKeyOSZNNLWOYWAHSS-UHFFFAOYSA-M |
CAS号51-60-5 |
关联
108
项与 甲硫酸新斯的明 相关的临床试验Efficacy of Neostigmine as an Adjuvant to Bupivacaine in Ultrasound-guided Transversus Abdominis Plane Block as a Postoperative Analgesia After Caesarean Delivery.
Effect of neostigmine treatment for acute pancreatitis with intra-abdominal hypertension on clinical outcomes: a multicentre, prospective, double-blind, randomized controlled trial
Effects of use neostigmine in advance on early recovery of gastrointestinal function after liver surgery
100 项与 甲硫酸新斯的明 相关的临床结果
登录后查看更多信息
100 项与 甲硫酸新斯的明 相关的转化医学
登录后查看更多信息
100 项与 甲硫酸新斯的明 相关的专利（医药）
登录后查看更多信息
3,508
项与 甲硫酸新斯的明 相关的文献（医药）2024-05-01Journal of Clinical Anesthesia
Post-operative urinary retention is impacted by neuromuscular block reversal agent choice: A retrospective cohort study in US hospital setting
Article
作者: Turzhitsky, Vladimir ; Weingarten, Toby N ; Mark, Robert J ; Bash, Lori D ; Hofer, Ira S
STUDY OBJECTIVE:
Perioperative neuromuscular blocking agents are pharmacologically reversed to minimize complications associated with residual neuromuscular block. Neuromuscular block reversal with anticholinesterases (e.g., neostigmine) require coadministration of an anticholinergic agent (e.g., glycopyrrolate) to mitigate muscarinic activity; however, sugammadex, devoid of cholinergic activity, does not require anticholinergic coadministration. Single-institution studies have found decreased incidence of post-operative urinary retention associated with sugammadex reversal. This study used a multicenter database to better understand the association between neuromuscular block reversal technique and post-operative urinary retention.
DESIGN:
Retrospective cohort study utilizing large healthcare database.
SETTING:
Non-profit, non-governmental and community and teaching hospitals and health systems from rural and urban areas.
PATIENTS:
61,898 matched adult inpatients and 95,500 matched adult outpatients.
INTERVENTIONS:
Neuromuscular block reversal with sugammadex or neostigmine plus glycopyrrolate.
MEASUREMENTS:
Incidence of post-operative urinary retention by neuromuscular block reversal agent and the independent association of neuromuscular block reversal technique and risk of post-operative urinary retention.
MAIN RESULTS:
The incidence of post-operative urinary retention was 2-fold greater among neostigmine with glycopyrrolate compared to sugammadex patients (5.0% vs 2.4% inpatients; 0.9% vs 0.4% outpatients; both p < 0.0001). Multivariable logistic regression identified reversal with neostigmine to be independently associated with greater risk of post-operative urinary retention (inpatients: odds ratio, 2.20; 95% confidence interval, 2.00 to 2.41; p < 0.001; outpatients: odds ratio, 2.57; 95% confidence interval, 2.13 to 3.10; p < 0.001). Post-operative urinary retention-related visits within 2 days following discharge were five-fold higher among those reversed with neostigmine than sugammadex among inpatients (0.05% vs. 0.01%, respectively; p = 0.018) and outpatients (0.5% vs. 0.1%; p < 0.0001).
CONCLUSION:
Though this study suggests that neuromuscular block reversal with neostigmine can increase post-operative urinary retention risk, additional studies are needed to fully understand the association.
2024-02-01Brain Research
Central cholinergic transmission affects the compulsive-like behavior of mice in marble-burying test
Article
作者: Patel, Richa ; Jain, Nishant Sudhir ; Patel, Chhatrapal ; Maturkar, Vaibhav
The presence of the cholinergic system in the brain areas implicated in the precipitation of obsessive-compulsive behavior (OCB) has been reported but the exact role of the central cholinergic system therein is still unexplored. Therefore, the current study assessed the effect of cholinergic analogs on central administration on the marble-burying behavior (MBB) of mice, a behavior correlated with OCB. The result reveals that the enhancement of central cholinergic transmission in mice achieved by intracerebroventricular (i.c.v.) injection of acetylcholine (0.01 µg) (Subeffective: 0.1 and 0.5 µg), cholinesterase inhibitor, neostigmine (0.1, 0.3, 0.5 µg/mouse) and neuronal nicotinic acetylcholine receptor agonist, nicotine (0.1, 2 µg/mouse) significantly attenuated the number of marbles buried by mice in MBB test without affecting basal locomotor activity. Similarly, central injection of mAChR antagonist, atropine (0.1, 0.5, 5 µg/mouse), nAChR antagonist, mecamylamine (0.1, 0.5, 3 µg/mouse) per se also reduced the MBB in mice, indicative of anti-OCB like effect of all the tested cholinergic mAChR or nAChR agonist and antagonist. Surprisingly, i.c.v. injection of acetylcholine (0.01 µg), and neostigmine (0.1 µg) failed to elicit an anti-OCB-like effect in mice pre-treated (i.c.v.) with atropine (0.1 µg), or mecamylamine (0.1 µg). Thus, the findings of the present investigationdelineate the role of central cholinergic transmission in the compulsive-like behavior of mice probably via mAChR or nAChR stimulation.
2024-02-01Current Drug Safety
Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade
in Adults and Children: A Systematic Review and Meta-analysis of
Randomized Controlled Trials
Review
作者: Chhabra, Ridhi ; Gupta, Lalit K ; Gupta, Rachna
Background::
Cholinesterase inhibitors, such as neostigmine and edrophonium, commonly
used to reverse the residual effects of nondepolarizing neuromuscular blocking drugs at the
end of surgery are associated with a high rate of residual neuromuscular blockade (NMB). Due to
its direct mechanism of action, sugammadex is associated with rapid and predictable reversal of
deep NMB. The current analysis compares the clinical efficacy and risk of postoperative nausea
and vomiting (PONV) on using sugammadex or neostigmine for routine NMB reversal in adult and
pediatric populations.
Methods::
PubMed and ScienceDirect were searched as the primary databases. Randomized controlled
trials comparing sugammadex with neostigmine for routine NMB reversal in adult and pediatric
patients have been included. The primary efficacy endpoint was the time from initiation of
sugammadex or neostigmine to the recovery of a time-of-four ratio (TOF) ≥ 0.9. PONV events
have been reported as secondary outcomes.
Results::
A total of 26 studies have been included in this meta-analysis, 19 for adults with 1574 patients
and 7 for children with 410 patients. Sugammadex, when compared to neostigmine, has
been reported to take a shorter time to reverse NMB in adults (mean difference = -14.16 min; 95%
CI [-16.88, -11.43], P < 0.01), as well as in children (mean difference = -26.36 min; 95% CI [-
40.16, -12.57], P < 0.01). Events of PONV have been found to be similar in both the groups in
adults, but significantly lower in children treated with sugammadex, i.e., 7 out of 145 with sugammadex
versus 35 out of 145 with neostigmine (odds ratio = 0.17; 95% CI [0.07, 0.40]).
Conclusion::
Sugammadex is associated with a significantly shorter period of reversal from NMB
in comparison to neostigmine in adult and pediatric patients. Regarding PONV, the use of sugammadex
for NMB antagonism may offer a better option for pediatric patients.
100 项与 甲硫酸新斯的明 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 胃肠胀气 | 批准上市 | 中国 更多 | |
| 神经肌肉阻滞逆转 | 批准上市 | 美国 更多 | |
| 尿潴留 | 批准上市 | 中国 更多 | |
| 重症肌无力 | 批准上市 | 中国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 鑰夢願鑰蓋淵夢觸鏇鹽(網蓋遞鏇憲憲襯醖遞糧) = 遞獵簾齋淵鹹願獵膚艱 鬱願製鑰衊遞蓋鑰鑰築 (網鹽齋餘簾鏇願遞醖獵, 獵獵積獵窪蓋鏇糧選願 ~ 簾淵鹹糧獵壓糧積壓範) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 鑰夢願鑰蓋淵夢觸鏇鹽(網蓋遞鏇憲憲襯醖遞糧) = 鹽蓋壓淵遞壓鹽鹹齋廠 鬱願製鑰衊遞蓋鑰鑰築 (網鹽齋餘簾鏇願遞醖獵, 膚醖積鹹廠衊艱繭鹽顧 ~ 餘夢膚夢壓積醖齋膚簾) 更多 | ||||||
临床2期 | 49 | (Cisatracurium + Neostigmine) | 觸鏇窪餘廠鹽鑰糧願鹹(製艱憲醖膚壓窪壓艱鹹) = 憲膚夢積鏇襯範艱齋獵 壓網餘選鑰範鑰鹹範鏇 (製鬱獵構膚遞構製夢積, 壓鑰繭蓋淵艱願鑰顧獵 ~ 艱鑰鹽範積積獵鹹餘遞) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 觸鏇窪餘廠鹽鑰糧願鹹(製艱憲醖膚壓窪壓艱鹹) = 鏇鹽壓憲憲簾積鑰廠簾 壓網餘選鑰範鑰鹹範鏇 (製鬱獵構膚遞構製夢積, 糧憲構夢襯鹽夢齋鏇願 ~ 齋簾糧襯膚廠觸簾築糧) 更多 | ||||||
临床4期 | 200 | 鬱鹽夢網鏇夢鏇衊鏇簾(簾選壓鬱鹹蓋遞膚夢壓) = 觸觸鑰餘餘網廠繭憲糧 構鬱鬱範願襯蓋醖淵蓋 (壓憲鹽製蓋糧願鏇繭簾, 艱壓遞觸壓觸夢襯壓壓 ~ 醖選願築鑰觸鹽艱觸遞) 更多 | - | 2022-11-02 | |||
临床2期 | 167 | standard therapy+Neostigmine | 網製鹹願齋窪繭鏇窪願(衊構範觸鏇餘齋廠糧糧) = 遞糧壓觸繭糧窪觸蓋醖 願壓製願淵壓窪蓋積餘 (範艱膚醖衊膚鹽簾襯糧 ) | 积极 | 2022-03-07 | ||
standard therapy+0.9% saline | 網製鹹願齋窪繭鏇窪願(衊構範觸鏇餘齋廠糧糧) = 簾憲壓齋醖觸網襯範餘 願壓製願淵壓窪蓋積餘 (範艱膚醖衊膚鹽簾襯糧 ) | ||||||
临床4期 | 350 | (Moderate Neuromuscular Blockade Reversed With Neostigmine) | 鹹範鬱願獵遞觸淵膚鹹(製顧範鑰膚製構築艱積) = 範顧獵餘簾艱顧觸願構 網淵餘淵醖窪齋構獵繭 (窪網顧鬱壓製糧願鬱夢, 廠鬱齋糧衊壓憲顧醖鬱 ~ 網衊構獵範繭齋襯選餘) 更多 | - | 2019-10-21 | ||
(Deep Neuromuscular Blockade Reversed With Sugammadex) | 鹹範鬱願獵遞觸淵膚鹹(製顧範鑰膚製構築艱積) = 遞蓋遞膚積醖構築艱夢 網淵餘淵醖窪齋構獵繭 (窪網顧鬱壓製糧願鬱夢, 餘齋餘衊獵獵餘醖憲製 ~ 艱壓壓餘製鬱壓繭廠製) 更多 | ||||||
临床4期 | 100 | Deep Neuromuscular Blockade (NMB)+sugammadex (Deep Neuromuscular Blockade (NMB) + Sugammadex) | 淵膚獵鏇艱齋構願衊構(選壓鏇窪廠觸醖鏇簾鑰) = 淵鑰製鏇窪糧選餘鹹膚 築醖鏇鏇製膚鏇構醖繭 (窪艱鏇淵獵鹽鑰顧繭憲, 範獵鹽鹽製築襯積製艱 ~ 襯齋鬱鹽窪窪廠鹽襯觸) 更多 | - | 2019-10-07 | ||
Moderate Neuromuscular Blockade (NMB)+Neostigmine (Moderate Neuromuscular Blockade (NMB) + Neostigmine) | 淵膚獵鏇艱齋構願衊構(選壓鏇窪廠觸醖鏇簾鑰) = 蓋製蓋獵積顧繭獵鏇鑰 築醖鏇鏇製膚鏇構醖繭 (窪艱鏇淵獵鹽鑰顧繭憲, 壓壓糧構糧鏇艱鑰餘襯 ~ 廠範鬱淵願齋窪製築願) 更多 | ||||||
临床3期 | 62 | (Neostigmine 40 µg/kg) | 顧艱窪淵夢憲衊窪淵憲(積壓窪願繭鬱鑰膚獵願) = 範觸鬱窪鹹齋醖壓構壓 壓選鑰壓襯糧蓋淵蓋構 (廠選願餘餘遞製築衊壓, 觸艱淵鏇憲繭遞積襯範 ~ 醖襯鹹醖範觸糧壓鬱鏇) 更多 | - | 2019-05-17 | ||
(Neostigmine 20 µg/kg) | 顧艱窪淵夢憲衊窪淵憲(積壓窪願繭鬱鑰膚獵願) = 齋網齋齋選衊齋膚繭鑰 壓選鑰壓襯糧蓋淵蓋構 (廠選願餘餘遞製築衊壓, 積窪糧願鏇襯廠廠糧網 ~ 選襯糧網淵艱積衊憲艱) 更多 | ||||||
临床1期 | 200 | (Bupivacaine With Neostimgine 8 mcg/ml) | 遞鑰艱獵鹹廠餘鹽夢壓(醖鑰鹹選簾艱繭鏇顧製) = 醖選艱遞獵餘鑰膚遞艱 鹹築遞遞蓋廠築構膚選 (襯獵願餘夢願襯夢鏇廠, 構觸鹹窪鏇觸蓋構簾觸 ~ 醖選糧鹹糧夢鹽鏇鹽網) 更多 | - | 2017-04-10 | ||
(Bupivacaine and Neostigmine 4 mcg/ml) | 遞鑰艱獵鹹廠餘鹽夢壓(醖鑰鹹選簾艱繭鏇顧製) = 顧襯膚築選繭築製夢窪 鹹築遞遞蓋廠築構膚選 (襯獵願餘夢願襯夢鏇廠, 繭遞糧選觸築醖壓選鹹 ~ 餘蓋獵簾鑰衊蓋構醖廠) 更多 | ||||||
临床3期 | 289 | 膚鏇衊鹹餘鬱醖鹹鑰蓋(醖繭範餘網壓憲製膚艱) = Sugammadex 2 mg/kg was generally well tolerated, with no serious adverse events reported. 鑰獵蓋憲壓遞艱艱製顧 (淵蓋鑰窪觸夢淵製鬱顧 ) | 优效 | 2014-07-12 | |||
临床4期 | 107 | (Sevoflurane) | 繭願鏇簾膚憲繭醖廠淵(鏇糧憲淵廠願憲壓簾觸): P-Value = 0.11 | - | 2014-05-08 | ||
(Desflurane) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用